Chrysa Mineo

Executive

Cidara Therapeutics, Inc.Receptos, Inc.

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 2 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€65k

▼ Sales (1 ops.)

€2.6M

Latest filing published 07 Jan 2026 for Cidara Therapeutics, Inc., €629k.

Filing timeline

BuySale

Chrysa Mineo

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Cidara Therapeutics, Inc. 2 purchases · last 04 Jun 2025

Chrysa Mineo: trading record in brief

Chrysa Mineo is a declared insider at 2 companies; the most frequent names are Receptos, Inc. and Cidara Therapeutics, Inc. Over a trading history stretching from 14 May 2013 to 7 January 2026, the count stands at 8 filings.

On the open market, the record shows 2 purchases worth €65k and 1 sale worth €2.6M. Sales outweigh purchases by €2.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant.

Most recently, on 7 January 2026, the filings show a transaction worth €629k in Cidara Therapeutics, Inc. The latest purchase dates back some time: it was published 507 days ago, on 4 June 2025. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.